Questions to Ask About Thyroid Cancer Treatment

"Thyroid cancer" covers four distinct diseases. NCI names them papillary, follicular, medullary, and anaplastic. For treatment planning NCI sorts them into two management categories. One is medullary thyroid cancer, a neuroendocrine cancer of the C cells. The other holds everything arising from the follicular cells, and NCI subdivides it by how differentiated the tumor is: well-differentiated covers papillary and follicular carcinoma and their recognised variants; poorly differentiated and undifferentiated cover anaplastic carcinoma. Anaplastic thyroid cancer is undifferentiated. Grouping it with papillary and follicular under one heading is a filing convenience, not a statement that it behaves like them, and its treatment has almost nothing in common with theirs.

Their outlooks are not close. Well-differentiated tumors are papillary and follicular. NCI calls them highly treatable and usually curable. Medullary thyroid cancer has an intermediate prognosis. Anaplastic thyroid cancer is less common, aggressive, spreads early, and carries a poorer prognosis.

So almost every other question here depends on the answer to this one. The American Cancer Society forecasts 45,240 new thyroid cancers in the United States for 2026, and 2,320 deaths, the figures SEER carries on its thyroid statistics page; NCI's PDQ summary still prints the 2025 estimates of 44,020 cases and 2,290 deaths. It affects women more often than men. It usually appears between ages 25 and 65. And its incidence has been rising over the last decade.

The gland can also host other primary cancers, including sarcoma and lymphoma. And it can be a site of spread from lung, breast, or kidney cancer.

For well-differentiated thyroid cancer, NCI states that age appears to be the single most important prognostic factor. That is unusual, and it has a concrete consequence in staging.

A retrospective series covered 1,807 patients. It found distant spread most predictive of survival, followed by age. It named 55 years as the best age cutoff. A validation across 9,484 patients followed, at many centers in many countries. That work is why the AJCC Cancer Staging Manual, 8th edition, moved the age cutoff. It went from 45 years to 55 years.

The effect on staging is stark. Stage II is the highest stage possible under age 55. Stage III and stage IV are only possible at 55 or older. Take two people with the same tumor, on either side of that birthday. They get different stage numbers.

Low-risk and high-risk grouping matters as much as the stage label. Low-risk criteria include women under 50 and men under 40 with no distant spread. They also include older patients with papillary tumors under 5 cm. Those tumors must show no gross growth outside the gland. And they include older patients with follicular cancer. That cancer must not have invaded the capsule or blood vessels. A retrospective study of 1,019 patients applied those criteria. Twenty-year survival was 98% for low-risk disease and 50% for high-risk disease.

A separate surgical series covered 931 patients not treated before. Five things counted against them. Age over 45. Follicular histology. A primary tumor larger than 4 cm. Growth outside the gland. And distant spread. Three things counted in their favor: female sex, multifocality, and regional lymph node involvement. Other studies found node involvement had no effect, or a bad one. NCI calls the meaning of node status controversial. That is worth knowing before reading too much into a node result.

These two behave differently, and the difference drives what gets watched.

Papillary carcinoma spreads to nearby lymph nodes more often than to distant sites. It is multifocal in as many as 50% of cases. That means present in more than one spot in the gland. Follicular carcinoma more often invades blood vessels. It travels in the blood to the lungs and bone. It does not favor the lymph system. Ten-year survival is better without vascular invasion than with it.

Most papillary cancers hold some follicular elements. Those may outnumber the papillary ones. NCI says they do not change the outlook. A follicular adenoma is different again. It lacks invasion through the capsule, and must be told apart from follicular carcinoma.

Questions that fit this group:

• Is the histology papillary, follicular, or mixed — and is there vascular invasion?
• Is the tumor multifocal?
• Is there extrathyroidal extension, and what is the size in centimeters?
• Which side of the 55-year cutoff does this fall on, and what stage results?
• Do the low-risk criteria apply here?
• Is radioactive iodine planned, and on what grounds?

NCI adds a caution on that last point. When spread occurs, radioiodine works at first. But the outlook worsens as resistance sets in. So whether the disease still responds to radioiodine is a question that recurs over years. It is not asked once.

Medullary thyroid cancer accounts for 3% to 4% of all thyroid cancers, and it comes with a genetics conversation attached.

Roughly 25% of reported cases are hereditary. In sporadic medullary cancer the tumor is usually one-sided. In the hereditary form it is almost always in both lobes. Hereditary cases may belong to a multiple endocrine neoplasia syndrome. MEN2A is the most common. MEN2B and hereditary non-MEN syndromes also exist. These are linked to pheochromocytoma of the adrenal gland. They are also linked to parathyroid hyperplasia. So anyone with a hereditary variant is screened for those too.

Two tests define this disease. Calcitonin is the hormonal marker. Medullary carcinoma usually makes it. It can show up in blood even when the tumor is hidden. But NCI is explicit about a limit. A modest calcitonin rise can produce a false-positive diagnosis. That is why testing for a RET gene variant is called the best approach. Everyone with medullary cancer is tested for RET variants. That holds whether the case is hereditary or sporadic. If a variant is found, family members are tested too. Relatives who carry one may choose to have the gland removed at an early age.

Some numbers to hold. Nearby lymph node spread is found in about 50% of medullary cases. Overall survival is 86% at 5 years and 65% at 10 years. Four factors count against: advanced age, advanced stage, previous neck surgery, and linked MEN2B.

Anaplastic cancer changes the timescale of every talk. It is an emergency in a way the other thyroid cancers are not: molecular testing, an airway assessment and a multidisciplinary plan are all needed within days, not weeks. All patients are counted as stage IV. It grows fast and reaches beyond the gland. It usually shows up as a hard, ill-defined mass. It occurs in an older age group. Five-year survival rates are poor. Death is usually from cancer in the neck that cannot be controlled. That often comes within months of diagnosis.

Two specific questions matter here more than anywhere else in thyroid cancer.

First: has lymphoma been excluded? NCI states that anaplastic thyroid cancer must be carefully told apart from lymphoma, which can present the same way. And lymphoma is treated completely differently.

Second: has BRAF V600E testing been done? An estimated 25% of these cancers carry an activating BRAF V600E variant. NCI advises molecular testing for it. One phase II trial paired two drugs. Dabrafenib blocks BRAF. Trametinib blocks MEK. The trial included 16 patients with anaplastic cancer and a BRAF V600E variant. The confirmed overall response rate was 69%. Twelve-month estimates were 90% for duration of response. They were 79% for progression-free survival and 80% for overall survival. On that data, the FDA approved the pair for anaplastic cancer with a BRAF V600E variant that cannot be removed, or has spread.

Other facts to plan around. This cancer does not respond to iodine I 131. About 30% of patients get a partial remission with doxorubicin. Doxorubicin plus cisplatin appears more active than doxorubicin alone. Removing the whole gland is warranted if the disease is local, which is rare. A tracheostomy is often needed. External-beam radiation may be used when surgery is not possible.

For differentiated thyroid cancer, thyroglobulin is the surveillance marker. A raised level tracks closely with recurrent tumor after surgery. One technical detail changes how the result reads. Thyroglobulin is most sensitive when a person is hypothyroid. The serum thyroid-stimulating hormone level has to be high. So it is fair to ask which hormone conditions a thyroglobulin was drawn under.

See thyroid cancer for the overview, and thyroid cancer treatment by stage for how stage maps onto options. For the "good cancer" framing, see the harmful "good cancer" label.

This page is a question list built from NCI. It does not recommend a treatment.

• NCI PDQ — Thyroid Cancer Treatment, health professional version
• American Cancer Society — Cancer Facts & Figures